Monkeypox virus

Tonix Pharmaceuticals’ Vaccine Candidate, TNX-1800, Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials

Retrieved on: 
Thursday, November 2, 2023
Monkeypox virus, FDA, National Institute of Allergy and Infectious Diseases, HHS, Food, Therapy, Vaccine, SARS-CoV-2, NIAID, Face, Mpox, Project, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Volunteering, Tonix Pharmaceuticals, Clinical trial, COVID-19, Smallpox, Nextgen, Animal, RPV, NIH, Safety, Office of Inspector General, U.S. Department of Health and Human Services, Infection, Tuberculosis, Bangladesh Technical Education Board

CHATHAM, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH), will conduct a Phase 1 clinical trial with TNX-1800 (recombinant horsepox virus, live vaccine),1 Tonix Pharmaceuticals’ vaccine candidate to protect against COVID-19.

Key Points: 
  • Tonix is developing a novel vaccine platform initially targeting COVID-19, smallpox and mpox (monkeypox).
  • The intent is to provide durable protection against severe disease and prevent forward transmission, primarily by eliciting a T-cell immune response.
  • “TNX-1800 will be the first vaccine candidate using our live virus recombinant pox virus (RPV) platform technology to enter clinical trials.
  • NIAID will be conducting clinical trials to evaluate several early-stage vaccine candidates.

U.S. Centers for Disease Control and Prevention Selects Verily to Support National Wastewater Monitoring

Retrieved on: 
Monday, October 2, 2023
Health, Infectious Diseases, Environment, Health Technology, Sustainability, COVID-19, Emory University, The New England Journal of Medicine, Centers for Disease Control and Prevention, SARS-CoV-2, Public, California Department, Infection, Stanford University, Doctor of Philosophy, CDC, MPXV, California Department of Public Health, Monkeypox virus, Public health, Verily, MD, Letter, NWSS, Vaccine

Verily, an Alphabet precision health technology company, today announced it was selected by the Centers for Disease Control (CDC) to support the agency’s National Wastewater Surveillance System (NWSS).

Key Points: 
  • Verily, an Alphabet precision health technology company, today announced it was selected by the Centers for Disease Control (CDC) to support the agency’s National Wastewater Surveillance System (NWSS).
  • The CDC launched NWSS in September 2020 to coordinate and build the nation’s capacity to track the presence of SARS-CoV-2 in wastewater samples collected across the country.
  • Verily’s Wastewater program offers wastewater surveillance to test for pathogens present in wastewater treatment facilities nationwide, allowing for timely detection and monitoring to inform public health actions.
  • Verily’s Wastewater program provides a robust measure of community infection trends at the height of surges when clinical testing can have insufficient capacity.

BioNTech and CEPI Announce Partnership to Advance mRNA Mpox Vaccine Development and Support CEPI’s 100 Days Mission

Retrieved on: 
Monday, September 18, 2023
Vaccine, Epidemic, BioNTech, Partnership, Vaccination, Public, Coalition, CEPI, Infection, Clinical trial, Malaria, Coalition for Epidemic Preparedness Innovations, Smallpox, History, Messenger, G7, MPXV, Monkeypox virus, Mpox, BNTX, G20, Knowledge, Pregnancy, Immunodeficiency, Virus, Safety, Tuberculosis, Orthopoxvirus

Since the eradication of smallpox in 1980, the global population-level immunity against the Orthopoxvirus viral family, including mpox, has been waning3.

Key Points: 
  • Since the eradication of smallpox in 1980, the global population-level immunity against the Orthopoxvirus viral family, including mpox, has been waning3.
  • BioNTech is aiming to develop a prophylactic mRNA-based mpox vaccine with a favorable safety profile that can be manufactured at scale.
  • The partnership between BioNTech and CEPI could help accelerate responses to future outbreaks caused by viruses of the Orthopoxvirus viral family in several ways.
  • BioNTech and CEPI are committed to enabling equitable access to the outputs of this partnership.

Blue Water Biotech Announces Preclinical Data Supporting Immunogenicity of Novel Monkeypox Vaccine Utilizing Norovirus Virus-Like Particle Platform

Retrieved on: 
Wednesday, June 28, 2023
Vaccine, S&P, Antigen, Human, Norovirus, Rotavirus, Vaccination, Biotechnology, Smallpox, Mpox, Capsid, Bluewater, Infection, Antibody, CDC, Monkeypox virus, Discovery, Animal, Patient, Risk, Blood, Korea Disease Control and Prevention Agency, VLP, Cincinnati Children's Hospital Medical Center, Mouse, FDA, Family, World Health Organization, Vaccinia

CINCINNATI, Ohio, June 28, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology and pharmaceutical company spanning multiple sectors, today announced preliminary preclinical data supporting the use of its norovirus shell and protrusion (“S&P”) virus-like particle (“VLP”) platform to develop a novel monkeypox vaccine candidate.

Key Points: 
  • CINCINNATI, Ohio, June 28, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology and pharmaceutical company spanning multiple sectors, today announced preliminary preclinical data supporting the use of its norovirus shell and protrusion (“S&P”) virus-like particle (“VLP”) platform to develop a novel monkeypox vaccine candidate.
  • In August 2022, Blue Water announced plans to explore the development of its novel monkeypox vaccine candidate by presenting monkeypox antigens within the S&P platform.
  • Following successful integration of selected antigens into the platform, mice were immunized with the vaccine candidate and analyzed for antibody levels in the blood.
  • “We are thrilled to announce this exciting initial step in development of our monkeypox vaccine candidate,” said Joseph Hernandez, Chairman and Chief Executive Officer of Blue Water.

Solaris Vaccines Adds Izabela Ragan as Director of Research and Development for the SolaVAX™ Platform

Retrieved on: 
Tuesday, April 18, 2023
Vaccine, Parasitism, Rift Valley fever, SARS-CoV-2, Colorado State University, African swine fever virus, Medicine, Infection, MERS-related coronavirus, Doctor of Philosophy, Monkeypox virus, Izabela, Kuyavian-Pomeranian Voivodeship, UV, Riboflavin, Bacteria, Health, Death, DVM, Disease, Tuberculosis, Research

FORT COLLINS, Colo., April 18, 2023 /PRNewswire-PRWeb/ -- Solaris Vaccines, Inc. announced today that Dr. Izabela Ragan (DVM, PhD), an expert in novel vaccine technologies, has joined as Director of Research and Development. The Company is developing a completely new approach to creating vaccines. Using Vitamin B2 in combination with UV light allows potentially any pathogen (virus, bacteria, parasite, fungus) to be rapidly transformed into a safe, effective and stable means of preventing disease and death. Proof of concept results for the platform technology—trademarked under the name SolaVAX™—have been obtained for SARS-CoV-2, Influenza, and Tuberculosis, with other infectious agents currently in progress.

Key Points: 
  • FORT COLLINS, Colo., April 18, 2023 /PRNewswire-PRWeb/ -- Solaris Vaccines, Inc. announced today that Dr. Izabela Ragan (DVM, PhD), an expert in novel vaccine technologies, has joined as Director of Research and Development.
  • The Company is developing a completely new approach to creating vaccines.
  • "I am excited to welcome Dr. Ragan to the Solaris team," said Dr. Michael Artinger, Solaris CEO.
  • According to Dr. Ragan, "Joining Solaris Vaccines is a natural next step in my career as I have seen firsthand the advantages of the SolaVAX platform in my previous work.

Europe Monkeypox Testing Market Research Report 2023: An $18.33 Billion Market in 2022 - Industry Outlook and Forecasts to 2025 - ResearchAndMarkets.com

Retrieved on: 
Monday, March 13, 2023
Biotechnology, Pharmaceutical, Health, Central African, Contact tracing, CE, European Commission, Smallpox vaccine, USD, Risk, Bavarian Nordic, European Medicines Agency, Government, NAAT, Research, European, Monkeypox virus, IVD, Orthopoxvirus, Pregnancy, MPXV, NHS, MPX, Division of Acquired Immunodeficiency Syndrome, Standing Commission on Pay Comparability, DNA, PCR, Growth, Civil service commission, Partnership, Joint Committee on Vaccination and Immunisation, National Health Service, Infection, Privacy and the US government, Cepheid (company), Mpox, Cepheid variable, Roche, EMA, Person, Vaccine, Viral, Medical device, Pharmaceutical industry, Vaccination, EU

The "Europe Monkeypox Testing Market - Industry Outlook and Forecast 2023-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Monkeypox Testing Market - Industry Outlook and Forecast 2023-2025" report has been added to ResearchAndMarkets.com's offering.
  • The Europe monkeypox testing market was valued at USD 18,330.00 thousand in 2022 and is expected to reach USD 56.10 thousand by 2025.
  • Increasing cases and testing are driving the growth of the Europe monkeypox testing market.
  • The growing product launches of lateral flow assay kits are expected to create lucrative opportunities for the Europe monkeypox testing market growth.

Mpox a Cause for Concern in Pregnant Persons

Retrieved on: 
Wednesday, March 1, 2023
Women, Other Health, Other Science, Parenting, Men, Research, Baby, Maternity, Infectious Diseases, Consumer, Science, Clinical Trials, Managed Care, General Health, Biotechnology, Health, Health Technology, Primary, Secondary, Health Insurance, Education, Infection, Smallpox, Cytomegalovirus, Skin, Viral, CAP, Stillbirth, Disease, Pathology, Pregnancy, College, Monkeypox virus, Mpox, Prevention, Liver, Fluid mechanics, Medical laboratory, Fetus, Woman, Archive, Archives of Pathology & Laboratory Medicine, COVID-19, Placenta, Health care, Vaccine, Birth control, MD

Mpox was known to infect pregnant persons in Africa, producing a 75 percent perinatal fatality rate.

Key Points: 
  • Mpox was known to infect pregnant persons in Africa, producing a 75 percent perinatal fatality rate.
  • They provide insight about how mpox can infect the fetus and describe details of a stillborn with placental infection, define and illustrate the Congenital Mpox Syndrome, and discuss mechanisms of intrauterine mpox transmission.
  • Although most mpox infections occurred in men, cases in women have increased, resulting in an intense concern for pregnant individuals acquiring the infection.
  • Healthcare providers should be aware that mpox occurring in pregnant persons is uncommon but has the capability to infect the fetus as well as the newborn and cause both perinatal morbidity and mortality.”

Global Monkeypox Treatment Market 2023 to 2035 - Featuring ACON Laboratories, altona Diagnostics, Jiangsu Bioperfectus Technologies and Elabscience Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 31, 2023
Infectious Diseases, Pharmaceutical, Health, Public health emergency of international concern, Vaccine, Laboratory, Human, Monkeypox virus, Therapy, Animal, Diagnosis, Viral disease, Contact tracing, World Health Organization, Developed country, ACAM2000, PCR, Patient, Cidofovir, Incidence, Research, PHEIC, Risk, WHO, Emergent, Disease, Growth, Smallpox, Public, Type, Polymerase chain reaction, Pharmaceutical industry, Mpox

In May 2022, multiple cases of the disease were reported in several non-endemic countries, thereby making monkeypox a disease of global concern.

Key Points: 
  • In May 2022, multiple cases of the disease were reported in several non-endemic countries, thereby making monkeypox a disease of global concern.
  • Consequently, in July 2022, the World Health Organization (WHO) declared global monkeypox outbreak a Public Health Emergency of International Concern (PHEIC).
  • Presently, more than 25 therapeutics / vaccines are commercialized / under development for the treatment and prevention of monkeypox.
  • Due to the surge in monkeypox cases in 2022, globally, there is a growing demand for monkeypox vaccines, therapeutics and diagnostic kits.

Laboratory Developed Tests Global Market Report 2022: Increasing Demand for Development of Personalized Medicine Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, January 23, 2023
Health, Biotechnology, Immunoassay, Segmental analysis (biology), Laboratory, Helmy Eltoukhy, Molecular diagnostics, Monkeypox virus, Colorectal cancer, Nutrition, LDT, Diagnosis, Breast cancer, Oncology, Patient, NHS England, DSM-IV codes, Quest Diagnostics, Genetics, Chapter Three, USD, Lung cancer, Laboratory developed test, Death, England, FDA, Growth, OPKO Health, Shield, Prevalence, Cancer, Infection, Ageing, Medical device, Pharmaceutical industry

The global laboratory developed tests market size is expected to reach USD 16.72 billion by 2030, expanding at a CAGR of 6.58% from 2023 to 2030.

Key Points: 
  • The global laboratory developed tests market size is expected to reach USD 16.72 billion by 2030, expanding at a CAGR of 6.58% from 2023 to 2030.
  • The growth of the industry is attributed to the increasing prevalence of chronic and genetic diseases, infectious & autoimmune diseases, and rising awareness among the population about healthy living.
  • The laboratory-developed tests (LDTs) are generated and utilized in the laboratories, and LDTs are released into the market without FDA approval or any other independent regulatory assessment.
  • Chapter 3 Laboratory Developed Tests Market Variables, Trends, & Scope
    Chapter 4 Laboratory Developed Tests Market - Segment Analysis, By Technology, 2018 - 2030 (USD Million)
    4.1 Laboratory Developed Tests Market: Technology Movement Analysis

Cepheid Receives Emergency Use Authorization from FDA for Xpert® Mpox

Retrieved on: 
Tuesday, February 14, 2023
World Health Organization, Certificate, Monkeypox virus, Cepheid (company), COC, EVP, PCR, Diagnosis, Cor, Measles, POC, Simplex, Human, Cedillo v. Secretary of Health and Human Services, Syphilis, Infection, Chickenpox, Cow, Fever, EUA, COA, Medical device, Vaccine, Xpert, Cepheid variable

SUNNYVALE, Calif., Feb. 14, 2023 /PRNewswire/ -- Cepheid today announced it has received Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration for Xpert Mpox, which runs on Cepheid's GeneXpert® systems. The EUA is supported by the Secretary of Health and Human Service's declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for the detection and/or diagnosis of infection with the monkeypox virus.

Key Points: 
  • SUNNYVALE, Calif., Feb. 14, 2023 /PRNewswire/ -- Cepheid today announced it has received Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration for Xpert Mpox, which runs on Cepheid's GeneXpert® systems.
  • Xpert Mpox is authorized for use in moderately complex settings and is considered authorized for use in point of care (POC) settings under the EUA for use on GeneXpert Xpress systems.
  • "Thankfully, the threat of mpox in the United States has decreased dramatically since last summer.
  • The World Health Organization recommends that suspected cases of mpox be confirmed with a PCR test run on an appropriate human lesion sample1.